Eckert & Ziegler Strahlen- und Medizintechnik AG Cash Flow Conversion Efficiency
Eckert & Ziegler Strahlen- und Medizintechnik AG cash flow conversion efficiency. Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) has a cash flow conversion efficiency ratio of 0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€18.75 Million ≈ $21.91 Million USD) by net assets (€253.42 Million ≈ $296.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)
Cash flow conversion efficiency of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025. This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EUZ stock price and chart for real-time trading data and today's change.
Eckert & Ziegler Strahlen- und Medizintechnik AG Cash Flow Conversion Ratio Explained
Eckert & Ziegler Strahlen- und Medizintechnik AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG ranked by their cash flow conversion efficiency. Also see Eckert & Ziegler Strahlen- und Medizinte market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CJ Korea Express
KO:000120
|
0.050x |
|
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
|
-0.447x |
|
Sipef NV
BR:SIP
|
0.138x |
|
SolGold Plc
F:S8F
|
0.128x |
|
Max Estates Limited
NSE:MAXESTATES
|
-0.096x |
|
Axis Real Estate Investment Trust
KLSE:5106
|
0.012x |
|
Hyundai Wia
KO:011210
|
-0.019x |
|
Azorim Investment Development and Construction Co Ltd
TA:AZRM
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)
The table below shows the annual cash flow conversion efficiency of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025. Review EUZ free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €253.42 Million ≈ $296.28 Million |
€58.41 Million ≈ $68.28 Million |
0.230x | -22.03% |
| 2024-12-31 | €225.21 Million ≈ $263.30 Million |
€66.57 Million ≈ $77.83 Million |
0.296x | +39.76% |
| 2023-12-31 | €224.09 Million ≈ $261.99 Million |
€47.40 Million ≈ $55.41 Million |
0.212x | +31.74% |
| 2022-12-31 | €213.63 Million ≈ $249.75 Million |
€34.30 Million ≈ $40.10 Million |
0.161x | -8.70% |
| 2021-12-31 | €192.53 Million ≈ $225.08 Million |
€33.85 Million ≈ $39.58 Million |
0.176x | -25.07% |
| 2020-12-31 | €148.92 Million ≈ $174.10 Million |
€34.95 Million ≈ $40.86 Million |
0.235x | -19.06% |
| 2019-12-31 | €139.44 Million ≈ $163.02 Million |
€40.43 Million ≈ $47.27 Million |
0.290x | +69.34% |
| 2018-12-31 | €123.88 Million ≈ $144.83 Million |
€21.21 Million ≈ $24.80 Million |
0.171x | -25.00% |
| 2017-12-31 | €117.52 Million ≈ $137.39 Million |
€26.83 Million ≈ $31.36 Million |
0.228x | +26.71% |
| 2016-12-31 | €110.08 Million ≈ $128.69 Million |
€19.83 Million ≈ $23.19 Million |
0.180x | +16.19% |
| 2015-12-31 | €104.67 Million ≈ $122.37 Million |
€16.23 Million ≈ $18.97 Million |
0.155x | +37.54% |
| 2014-12-31 | €94.49 Million ≈ $110.47 Million |
€10.65 Million ≈ $12.45 Million |
0.113x | -30.65% |
| 2013-12-31 | €90.27 Million ≈ $105.53 Million |
€14.68 Million ≈ $17.16 Million |
0.163x | -- |
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more